Lilly to Launch $149/Month Oral GLP-1 Pill Foundayo on April 6
Eli Lilly won FDA approval for its oral GLP-1 weight-loss drug Foundayo, set to launch April 6 at a $149 monthly cash-pay price and a $25 commercial-insurance copay rising to $50 under Medicare Part D. Foundayo’s filings in 40 countries challenge Novo Nordisk’s Wegovy and reshape the $50 billion obesity market.
1. FDA Approval and Launch
After winning FDA approval, Eli Lilly will launch Foundayo on April 6 as its first oral GLP-1 weight-loss therapy. The company set the cash-pay starter dose at $149 per month, matching the price of competitive pills, and plans to begin commercial distributions immediately following launch.
2. Pricing and Insurance Structure
Patients paying cash will incur a $149 monthly cost while those on commercial insurance face a $25 copay; Medicare Part D enrollees will pay $50 per month. Lilly’s pricing strategy aims to balance affordability with market penetration against existing injectable and oral competitors.
3. Safety Profile and Dosage Guidelines
Foundayo includes a thyroid tumor boxed warning and limits simvastatin dosing to 20 mg at the starter dose, prohibits strong CYP3A4 inducers and restricts strong CYP3A4 inhibitors to a 9 mg maximum. Unlike rival pills, it imposes no 30-minute post-dose fasting requirement, potentially enhancing patient convenience.
4. Global Rollout and Competitive Impact
Lilly has filed for approval of Foundayo in 40 countries, potentially outpacing incumbent products in key markets. This broad international filing strategy and competitive pricing could pressure Novo Nordisk’s Wegovy sales, potentially reshaping the $50 billion obesity treatment market.